Theresa D’Aquila

发表

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

Michael D. Hamilton, J. Pfefferkorn, N. Barucci, 2012, Bioorganic & medicinal chemistry letters.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk

T. Rolph, J. Pfefferkorn, K. Borzilleri, 2014 .

Intestinal cytoplasmic lipid droplets, associated proteins, and the regulation of dietary fat absorption

Theresa D’Aquila, 2016 .

Acyl CoA synthetase 5 (ACSL5) ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption

D. Mashek, A. Greenberg, Qingwu Yan, 2016, Molecular metabolism.

The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats

J. Trimmer, T. Rolph, Jiangli Yan, 2014, PloS one.

Characterization of cytoplasmic lipid droplets in each region of the small intestine of lean and diet-induced obese mice in the response to dietary fat.

K. Buhman, Theresa D’Aquila, Alyssa S. Zembroski, 2021, American journal of physiology. Gastrointestinal and liver physiology.

Diet Induced Obesity Alters Intestinal Cytoplasmic Lipid Droplet Morphology and Proteome in the Postprandial Response to Dietary Fat

K. Buhman, Theresa D’Aquila, Alyssa S. Zembroski, 2019, Front. Physiol..

Recent discoveries on absorption of dietary fat: Presence, synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes.

K. Buhman, Alicia L. Carreiro, Y. Hung, 2016, Biochimica et biophysica acta.

Characterization of the Proteome of Cytoplasmic Lipid Droplets in Mouse Enterocytes after a Dietary Fat Challenge

Devika Sirohi, R. Kuhn, A. Greenberg, 2015, PloS one.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.